Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment BOCA RATON, FL – October 19, 2020 – Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients. Akron

COVID-19 Response

Akron Biotech is committed to help defeat COVID-19 – Together we cure Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms tend to appear 2-14 days after exposure to the virus and can range from mild to severe, with some patients requiring  hospitalization1. In response to this

COVID-19 Virus Notice

A Note to Our Valued Partners Regarding COVID-19   As we continue to deal with the challenges and uncertainty of Covid-19 Virus, our priority is to ensure the safety of our employees while minimizing any potential impact to our valued customers and partners.  Therefore, we are taking all the necessary precautions to ensure that our